世界の標的化ドラッグデリバリーシステム市場(~2027):製品別、用途別、地域別

【英語タイトル】Targeted Drug Delivery System Market Research Report by Product, Application, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

360iResearchが出版した調査資料(MRC2305D143)・商品コード:MRC2305D143
・発行会社(調査会社):360iResearch
・発行日:2022年10月
・ページ数:254
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後2-3日)
・調査対象地域:グローバル
・産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名利用、印刷可)USD4,949 ⇒換算¥752,248見積依頼/購入/質問フォーム
Enterprise License(企業利用、印刷可)USD9,949 ⇒換算¥1,512,248見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

360iResearch社は、2021年に5,832.89百万ドルであった世界の標的化ドラッグデリバリーシステム市場規模が、2022年に6,884.29百万ドルに成長し、更に年平均18.20%拡大して2027年までに15,908.86百万ドルに達すると予測しています。当市場調査レポートでは、標的化ドラッグデリバリーシステムの世界市場を多角的に分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、製品別(ナノプロ、ナノシェル、ナノチューブ、ナノワイヤー、量子ドット)分析、用途別(一次ターゲティング(臓器区画化)、二次ターゲティング(セルラーターゲティング)、三次ターゲティング(細胞内ターゲティング))分析、地域別(南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他)分析、競争状況、企業情報などの内容を掲載しています。また、当書内の企業情報には、3M Company、AbbVie Inc.、Ablynx NV by Sanofi SA、Arrowhead Pharmaceuticals, Inc.、AstraZeneca PLC、Baxter International Inc.、Becton, Dickinson and Company、Boston Scientific Corporation、Depomed, Inc. by Horizon Pharma PLCなどが含まれています。
・序論
・調査方法
・エグゼクティブサマリー
・市場概要
・市場インサイト
・世界の標的化ドラッグデリバリーシステム市場規模:製品別
- ナノプロの市場規模
- ナノシェルの市場規模
- ナノチューブの市場規模
- ナノワイヤーの市場規模
- 量子ドットの市場規模
・世界の標的化ドラッグデリバリーシステム市場規模:用途別
- 一次ターゲティング(臓器区画化)における市場規模
- 二次ターゲティング(セルラーターゲティング)における市場規模
- 三次ターゲティング(細胞内ターゲティング)における市場規模
・世界の標的化ドラッグデリバリーシステム市場規模:地域別
- 南北アメリカの標的化ドラッグデリバリーシステム市場規模
アメリカの標的化ドラッグデリバリーシステム市場規模
カナダの標的化ドラッグデリバリーシステム市場規模
ブラジルの標的化ドラッグデリバリーシステム市場規模
...
- アジア太平洋の標的化ドラッグデリバリーシステム市場規模
日本の標的化ドラッグデリバリーシステム市場規模
中国の標的化ドラッグデリバリーシステム市場規模
インドの標的化ドラッグデリバリーシステム市場規模
韓国の標的化ドラッグデリバリーシステム市場規模
台湾の標的化ドラッグデリバリーシステム市場規模
...
- ヨーロッパ/中東/アフリカの標的化ドラッグデリバリーシステム市場規模
イギリスの標的化ドラッグデリバリーシステム市場規模
ドイツの標的化ドラッグデリバリーシステム市場規模
フランスの標的化ドラッグデリバリーシステム市場規模
ロシアの標的化ドラッグデリバリーシステム市場規模
...
- その他地域の標的化ドラッグデリバリーシステム市場規模
・競争状況
・企業情報

The Global Targeted Drug Delivery System Market size was estimated at USD 5,832.89 million in 2021 and expected to reach USD 6,884.29 million in 2022, and is projected to grow at a CAGR 18.20% to reach USD 15,908.86 million by 2027.

Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:
This research report categorizes the Targeted Drug Delivery System to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Product, the market was studied across Nano Pros, Nano Shells, Nano Tubes, Nano Wires, and Quantum Dots.

Based on Application, the market was studied across First Order Targeting (Organ Compartmentalization), Second Order Targeting (Cellular Targeting), and Third Order Targeting (Intracellular Targeting).

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Targeted Drug Delivery System market considering the current update on the conflict and its global response.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Targeted Drug Delivery System Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Targeted Drug Delivery System Market, including 3M Company, AbbVie Inc., Ablynx NV by Sanofi SA, Arrowhead Pharmaceuticals, Inc., AstraZeneca PLC, Baxter International Inc., Becton, Dickinson and Company, Boston Scientific Corporation, Depomed, Inc. by Horizon Pharma PLC, Fraunhofer Gesellschaft München, Janssen Global Services, LLC, Luye Pharma Group, Pfizer Inc., Quark Pharmaceuticals Inc., Rexahn Pharmaceuticals Inc., Roche Holding AG, Savara Inc., Suda Limited, Taiwan Liposome Company, Ltd., and Vectura Group PLC.

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Global Targeted Drug Delivery System Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Targeted Drug Delivery System Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Targeted Drug Delivery System Market?
4. What is the competitive strategic window for opportunities in the Global Targeted Drug Delivery System Market?
5. What are the technology trends and regulatory frameworks in the Global Targeted Drug Delivery System Market?
6. What is the market share of the leading vendors in the Global Targeted Drug Delivery System Market?
7. What modes and strategic moves are considered suitable for entering the Global Targeted Drug Delivery System Market?

❖ レポートの目次 ❖

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising geriatric and pediatric population globally
5.1.1.2. Increasing need for enhanced delivery of drug systems with prevalence of chronic human diseases
5.1.2. Restraints
5.1.2.1. Complexity in development of efficient targeted drug-delivery systems
5.1.3. Opportunities
5.1.3.1. Increasing adoption of nanotechnology
5.1.3.2. Advances in biotechnology to develop non-invasive drug-delivery technologies
5.1.4. Challenges
5.1.4.1. Issues related to unwanted adverse effects
5.2. Cumulative Impact of COVID-19

6. Targeted Drug Delivery System Market, by Product
6.1. Introduction
6.2. Nano Pros
6.3. Nano Shells
6.4. Nano Tubes
6.5. Nano Wires
6.6. Quantum Dots

7. Targeted Drug Delivery System Market, by Application
7.1. Introduction
7.2. First Order Targeting (Organ Compartmentalization)
7.3. Second Order Targeting (Cellular Targeting)
7.4. Third Order Targeting (Intracellular Targeting)

8. Americas Targeted Drug Delivery System Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Targeted Drug Delivery System Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam

10. Europe, Middle East & Africa Targeted Drug Delivery System Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom

11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis, By Key Player
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion

12. Company Usability Profiles
12.1. 3M Company
12.1.1. Business Overview
12.1.2. Key Executives
12.1.3. Product & Services
12.2. AbbVie Inc.
12.2.1. Business Overview
12.2.2. Key Executives
12.2.3. Product & Services
12.3. Ablynx NV by Sanofi SA
12.3.1. Business Overview
12.3.2. Key Executives
12.3.3. Product & Services
12.4. Arrowhead Pharmaceuticals, Inc.
12.4.1. Business Overview
12.4.2. Key Executives
12.4.3. Product & Services
12.5. AstraZeneca PLC
12.5.1. Business Overview
12.5.2. Key Executives
12.5.3. Product & Services
12.6. Baxter International Inc.
12.6.1. Business Overview
12.6.2. Key Executives
12.6.3. Product & Services
12.7. Becton, Dickinson and Company
12.7.1. Business Overview
12.7.2. Key Executives
12.7.3. Product & Services
12.8. Boston Scientific Corporation
12.8.1. Business Overview
12.8.2. Key Executives
12.8.3. Product & Services
12.9. Depomed, Inc. by Horizon Pharma PLC
12.9.1. Business Overview
12.9.2. Key Executives
12.9.3. Product & Services
12.10. Fraunhofer Gesellschaft München
12.10.1. Business Overview
12.10.2. Key Executives
12.10.3. Product & Services
12.11. Janssen Global Services, LLC
12.11.1. Business Overview
12.11.2. Key Executives
12.11.3. Product & Services
12.12. Luye Pharma Group
12.12.1. Business Overview
12.12.2. Key Executives
12.12.3. Product & Services
12.13. Pfizer Inc.
12.13.1. Business Overview
12.13.2. Key Executives
12.13.3. Product & Services
12.14. Quark Pharmaceuticals Inc.
12.14.1. Business Overview
12.14.2. Key Executives
12.14.3. Product & Services
12.15. Rexahn Pharmaceuticals Inc.
12.15.1. Business Overview
12.15.2. Key Executives
12.15.3. Product & Services
12.16. Roche Holding AG
12.16.1. Business Overview
12.16.2. Key Executives
12.16.3. Product & Services
12.17. Savara Inc.
12.17.1. Business Overview
12.17.2. Key Executives
12.17.3. Product & Services
12.18. Suda Limited
12.18.1. Business Overview
12.18.2. Key Executives
12.18.3. Product & Services
12.19. Taiwan Liposome Company, Ltd.
12.19.1. Business Overview
12.19.2. Key Executives
12.19.3. Product & Services
12.20. Vectura Group PLC
12.20.1. Business Overview
12.20.2. Key Executives
12.20.3. Product & Services

13. Appendix
13.1. Discussion Guide
13.2. License & Pricing



★調査レポート[世界の標的化ドラッグデリバリーシステム市場(~2027):製品別、用途別、地域別] (コード:MRC2305D143)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の標的化ドラッグデリバリーシステム市場(~2027):製品別、用途別、地域別]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆